Latest stories on GANX
Gain Therapeutics Reports Q2 Eps 11c Consensus 15c
The Fly42 · neutralearnings
Gain Therapeutics GAAP EPS of -$0.11 beats by $0.03
Seeking Alpha56 · neutralearnings
Gain Therapeutics Reports Financial Results for Second Quarter 2026 and Provides Corporate Update
StockTitan55 · neutralgeneral
Gain Therapeutics, Inc. (GANX) files 8-K
SEC 8-K50 · neutralgeneral
Gain Therapeutics CEO Gene Mack Issues Letter to Shareholders and Provides Operational Update
Business Insider55 · neutralgeneral
Gain Therapeutics Gets FDA Approval to Start Phase 2 Study of Parkinson's Drug
Morningstar63 · neutralproduct/pr
Why Is GANX Stock Rallying 22% After Hours?
Stocktwits News73 · bullishproduct/pr
Gain Therapeutics advances GT-02287 into Phase 2 Parkinson’s trial
TipRanks63 · neutralproduct/pr
Gain Therapeutics, Inc. (GANX) files 8-K
SEC 8-K50 · neutralgeneral
Gain Therapeutics Shareholders Confirm Board and Auditor Choices
TipRanks50 · neutralgeneral
Gain Therapeutics, Inc. (GANX) files 8-K
SEC 8-K50 · neutralgeneral
Gain Therapeutics to Present at H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit | GANX Stock News
StockTitan56 · neutralgeneral
Gain Therapeutics Reports Interim Data for Parkinson’s Candidate
TipRanks59 · neutralproduct/pr
Gain Therapeutics (GANX) Shares Edge Higher After Narrower-Than-Expected Q1 Loss
Yahoo Top56 · neutralearnings